Sponsored by

PuffItUp Dynavap VGoodiez 420EDC
  • Welcome to VaporAsylum! Please take a moment to read our RULES and introduce yourself here.
  • Need help navigating the forum? Find out how to use our features here.
  • Did you know we have lots of smilies for you to use?

Law Canada MJ News


Well-Known Member
Canada's Marijuana Industry Has a New Problem

For years, cannabis stocks were the greatest thing since sliced bread on Wall Street. The expectation of ongoing state-level legalization in the U.S., coupled with Canada becoming the first industrialized country in the modern era to give marijuana the green light, was forecast to send pot stock valuations into the heavens -- and for a period of time this is precisely what happened.
However, marijuana stock investors have received a dose of reality since the end of March 2019. Supply issues have been persistent throughout Canada, whereas exorbitant tax rates on legal weed remain problematic in the United States. Though the long-term outlook for the legal pot industry is still very compelling, the near-term appears challenging.
This is especially true for the Canadian marijuana industry.
Canadian pot stocks appeared to have a clear path to outperform in Q2
Canada was expected to be a cannabis leader, but it completely blew its chance to be the industry's blueprint due to regulatory-based miscues and overzealous capacity expansion.
Then again, Canada looked to be turning the corner during the coronavirus disease 2019 (COVID-19) pandemic. According to Statistics Canada, revenue from licensed cannabis stores has been hitting record highs. Here are the latest monthly cannabis store sales figures (all figures in Canadian dollars (CA$)):
  • March: CA$181.2 million
  • April: CA$178.4 million
  • May: CA$185.9 million
For context, January and February generated respective cannabis store sales of CA$154.1 million and CA$151.9 million. With new dispensaries opening in key provinces, such as Ontario, and consumers apparently stockpiling cannabis in advance of stay-at-home orders in Canada that were tied to the pandemic, it was my expectation that Canadian pot stocks would come roaring out of the gate when reporting their May-or-June-ended quarterly results.
Oh how wrong I've been.
A cannabis leaf lying atop a one hundred dollar bill, with Ben Franklin's eyes peering between the leaves.

Image source: Getty Images.
The Canadian weed industry has a new problem on its hands

Through this past week, we've witnessed two of Canada's major licensed producers unveil their latest quarterly operating results. In both instances, even with Canadian licensed pot sales up notably since the year began, the licensed producers delivered underwhelming results.
Last week, it was Cronos Group (NASDAQ:CRON), which reported almost $9.9 million in quarterly sales, $2.17 million of which originated in the United States. Unfortunately, Cronos wrote down more than $3 million in inventory, which, in addition to $9.8 million in cost of goods sold, led to a gross loss of $3 million and an operating loss of $34.8 million for the quarter.
Prior to Cronos Group, it was New Brunswick-based OrganIGram Holdings (NASDAQ:OGI) delivering a dud. OrganiGram's May-ended quarter featured CA$18 million in net sales, down from CA$24.8 million in net sales in the prior-year quarter. On an operating basis, and inclusive of an unfavorable fair-value adjustment on biological assets, OrganiGram produced a loss from operations of a staggering CA$99.3 million.
Though there's plenty of finger-pointing to go around following these abysmal results, one particular similarity stands out with these companies: They both placed some degree of blame on falling net selling prices for cannabis.
In Cronos Group's press release, it was worded as "cannabis product price compression in the Canadian market." Meanwhile, OrganiGram's press release referred to it as "a lower average price driven by increased competition."
The point is, the Canadian marijuana industry has a brand-new problem: Plunging dried flower prices.
A judge's gavel next to a handful of dried cannabis buds.

Image source: Getty Images.
Three reasons Canada's marijuana flower prices are falling
How is it that the net selling price of cannabis could be in free-fall when the Canadian weed industry is still relatively nascent?
To begin with, some of the blame can be assigned to regulators. In Ontario, provincial regulators stood by an ineffective lottery licensing system for dispensaries until Dec. 31, 2019, before abandoning it for a more traditional application and vetting process. This lottery system left Ontario completely unprepared -- a mere 24 stores were open by mid-October 2019 -- and led to significant supply bottlenecks in the region.
Secondly, licensed produces are partly to blame. Without any precedent to a legal marijuana industry in an industrialized country, pot stocks expanded their production capacity and made acquisitions without really understanding the ramifications of their decisions. In recent months, dried flower has flooded a market that simply doesn't have enough dispensaries to sell it.
And third, the black market remains a nuisance for the Canadian cannabis industry. With taxes being levied on legal weed purchases, the only way for pot stocks to be price-competitive with the illicit industry is by producing value-branded product. While these value brands can help lure in legal-channel consumers, they've been absolutely wrecking margins and the push toward profitability (see Cronos and OrganiGram).
At this point, Canadian marijuana stocks are left with a tough choice. On one hand, they could produce a value brand in order to take on the black market and potentially secure a loyal following of consumers. Then again, doing so will wreck near-term margins. On the other hand, they can target premium product and risk not gaining significant market share, but preserve their margins in the process.
The correct path is anyone's guess at this point, which is what continues to make Canadian pot stocks a risky investment.


Well-Known Member
In Maryland we are now seeing daily specials at $30-35 per eighth which is way down from $65 that was unbiqutous when the program opened. Some mid-teens but some high teens very low 20's on percentage THC.

Canadian pot producers take fight to illicit market with cheap cannabis

It took some time, but Canadian cannabis producers appear to have finally embraced selling cheaper pot.
The so-called value segment of the Canadian cannabis market - defined by one analyst as having a retail price below $6 per gram - has exploded in recent months: it accounted for slightly more than 40 per cent of all dried flower sales in July, up from 10 per cent of the market last September, according to industry data provider Headset.

The popularity of these “value" products has helped companies like Aurora Cannabis Inc. and Canopy Growth Corp. report better-than-expected quarterly sales figures, while also providing consumers with a competitively priced product that could lure people away from the illicit market.
"The value segment is really aimed at getting people in [the legal market], but the producer's job is to keep that customer and then trade them up to more expensive products," said Graeme Kreindler, an analyst with Eight Capital, in a phone interview.
But their prevalence may come at a price. By selling more cheap pot, cannabis companies may risk hurting their margins as well as sacrificing additional revenue despite being able to clear out inventory much faster, some analysts say.
There were more than 669,000 kilograms of unpackaged dried flower stored in cannabis producers' vaults across Canada in May, according to recent Health Canada figures. That could take well over a year to clear out assuming no more pot is produced in the country and if inventory isn't destroyed.
"What's been interesting to me was how some of the Canadian producers didn't understand that they could maintain higher prices per volume on flower products," said Stifel Financial Corp. analyst Andrew Carter in an interview.

"With excess capacity, there's always going to be someone that eventually decides to undercut everyone else."

That's what happened in October when Hexo Corp. launched its Original Stash brand, which sold about one ounce of cannabis for approximately $125, a price point that would match similar products found on the illicit market. Now, there is roughly a dozen cannabis producers who are selling similar sized options to the recreational market.
Carter said Canopy Growth recently embraced the value segment with cheaper bulk options after the company lost market share and needed to spur sales.
"If they can focus on growth, then maybe [Canopy] can win back some of its market share," he said.

Bloomberg Markets To win in cannabis, you need to win the recreational market: Canopy Growth CEO

To win in cannabis, you need to win the recreational market: Canopy Growth CEO

Canopy Growth CEO David Klein says his company intends to have top market share in each recreational segment which means improving flower quality and encouraging the entry of non-smoking consumers into the cannabis space through topicals and beverages.

Earlier this week, David Klein, chief executive officer at Canopy Growth, said that the value segment of the market is likely to command about half of the overall recreational market.

However, it might take a few more years for the Canadian cannabis market to show the various distinctive segments of the market such as value offerings or premium brands, he added.

"The consumer is just defaulting to the highest THC for the lowest price right now," Klein told BNN Bloomberg in a phone interview.
"Most of the [consumer-packaged-goods] categories like to define themselves by price points, but I don't know if the price points have been established yet in a meaningful way. We'll only know that once we go through this transition from the illicit market to the legal market."

While B.C.-based Tilray Inc. does offer a value product under its The Batch brand, it hasn't been a strategic focus for the company, said RBC Capital Markets analyst Douglas Miehm, in a recent research note.
"[Tilray] is targeting sales from higher-margin products, which in our view could hinder its revenue and [earnings before interest, taxes, depreciation, and amortization] ramp," he wrote.

Tilray CEO Brendan Kennedy said in an interview that he doesn't see cheaper cannabis on the legal market stopping customers from buying the pot producer's more expensive premium offerings. Indeed, he said people who are more interested in higher-quality products with better terpene profiles or visual appeal aren't the target market for value brands.

"A net new value consumer is coming from the illicit market, generally, and not coming from a premium segment of the market. So I don't see cannibalization," Kennedy said. "If we see the value market growing over time, that's probably a good thing because those value consumers are migrating from the illicit market."


Vapor Accessory Addict
Staff member
Niagara site significant part of $42-million cannabis drug bust

Law enforcement agencies cracked down on what Ontario Provincial Police described as an international “criminal enterprise” last week, seizing an estimated $42 million in drugs, equipment, weapons and other items, and arresting eight suspects.

A Jordan greenhouse surrounded by police Aug. 13 was likely one of 26 locations searched by officers last week that also included places in Niagara Falls, St. Catharines, Welland, Simcoe, Markham, Canfield, Leamington, Scarborough, Richmond Hill and British Columbia, at the culmination of a year-long investigation dubbed Project WOOLWICH.

Police says members of the criminal enterprise had been exploiting Health Canada medical, personal and designate cannabis production, instead growing the plant to sell illegally, including in the U.S.

Det. Insp. Jim Walker, from the OPP’s organized crime enforcement bureau and provincial joint forces cannabis enforcement team, said investigators have learned criminal enterprises are abusing Health Canada registration, using it as a loophole to grow well over what their allotment is.

“They’re flagrantly overgrowing that amount, so now you have these large-scale cannabis farms under the regime of Health Canada that they hide behind,” Walker said in a video released Friday by the OPP.

Investigators say shipments of U.S.-bound illegal cannabis were also seized, as well as two shipments of U.S. currency being shipped to Canada – leading to the involvement of U.S. Homeland Security Investigations offices in Buffalo and Toronto.

Michael Buckley, the Homeland Security Investigations attaché at the U.S. Embassy in Ottawa, called the joint investigation “an excellent example of the ongoing collaboration between the Homeland Security Investigations … the Ontario Provincial Police and Niagara Regional Police.”

“It clearly highlights that the critical sharing of information can successfully lead to the dismantlement of criminal organizations in both countries,” he said in a media release.


Vapor Accessory Addict
Staff member
Medically validating pot: Canada’s first medical cannabis clinical trial

Across the U.S., thousands of medical patients use cannabis to treat their anxiety, chronic pain, sleeplessness, arthritis and even epilepsy every day, as medical marijuana is legal in 24 states.

But because of its federal status as a Schedule 1 substance, medicinal cannabis has not been standardized like other pharmaceutical drugs in this country. It’s stuck in a catch-22: by definition, a Schedule 1 substance has no medicinal value. But its Schedule 1 classification also largely prevents research to prove the medicinal value of cannabis.

Canada legalized cannabis at a national level in 2018, though, so studying and doing legal research on the drug is much easier north of the U.S. border. There, medical professionals like Dr. Hance Clarke are eager to start standardizing medicinal cannabis for patients and physicians everywhere.

The medicinal variability between brands of products and even batches from the same brand makes it challenging for patients and doctors to know exactly what they’re getting or prescribing in an edible, a tincture, a strain of flower, hash or oil, Clarke says. But that’s something he hopes to change.

“Recreational products have a variation of anywhere from 10-22%,” Clarke says. “That’s cool if it’s in the recreational zone. It’s not good if you have a complex medical condition that you’re looking to treat and you want the medication to have the same effect on your symptoms every time you consume it.”

He adds that 10-22% variability is not acceptable in any other type of pharmaceutical product.

Clarke is the director of pain services at Toronto General hospital and a recognized leader in opioid abuse education in Canada. Now, he’s working to validate and standardize cannabis as a medicine in Canada’s medical world.

In a clinical trial, called Medical Cannabis Real-World Evidence (MC-RWE), researchers aim to first test the reliability and repeatability of Canadian cannabis products, and then to create a national repository of cannabis product data for physicians and patients. With the help of 2,000 Canadian trial subjects, they’re going to test products from 12 of Canada’s leading cannabis producers.

“We’ve got to convince [physicians] that what they order or prescribe, they can get the next time, if they see a benefit,” Clarke says. “The real game-changer is going to be that you can search for and find exactly the product that’s going to treat your symptom, without being beholden to the variability of the industry.”

To participate in the study, patients must experience depression, chronic pain, sleeplessness or anxiety. Once accepted, those patients will go to an online portal created by California blockchain company True Trace (MCRWE.ca), and select from products that have been genetically tested and monitored from seed to sale.

Patients will closely track their own symptoms over the course of six months, answering three detailed medical questionnaires on the True Trace portal. Researchers will monitor the patients’ progress through the trial, but won’t interfere in the observational study.

So far, Clarke says the trial only has about 50 out of the 2,000 testers researchers hope to sign up, and they’re accepting applications from any Canadian who would like to participate.

When the six-month trial is over, Clarke’s hope is to have a comprehensive national repository of cannabis products and associated data that physicians and patients can consult. They’ll be able to see exactly what symptoms each product works to relieve and how consistent the relief is. They’ll be able to search for a product by the symptom it relieves, see which top five cannabinoids are present in it, and what people said about the terpene profile.

“If I’m a physician, what products do I want my patients to be taking? Something that I know is validated, something that I know is replicable,” says Clarke. “So as a licensed producer, if you want that type of medical credibility, you’re going to certainly want to consider being part of the platform as well.”

And the more the merrier, as far as Clarke is concerned. The broader the scope of producers, the more researchers will learn about these products and the more useful Clarke’s online repository becomes for patients and physicians.

It’s a service that will undoubtedly help a lot of Canadian patients suffering from different ailments find exactly the cannabis medicine that’s right for them. And it’s a service that will help Canadian physicians get their patients the most reliable, effective and least health adverse medicines.

It’s a service that the U.S. could greatly benefit from. But one which won’t be possible, until the substance itself finds its way off that federal list of Schedule 1 drugs.


Vapor Accessory Addict
Staff member
Manitoba man taking province, attorney general to court over ban on growing pot at home

There is a precedent: Quebec's ban was ruled unconstitutional on Sept. 3, 2019

One man is aiming to make it legal for all Manitobans to grow weed at home.

Jesse Lavoie filed a notice of application on Wednesday against the Manitoba government and the attorney general to strike down a section of the province's Liquor, Gaming and Cannabis Control Act that bans home growth operations.

"I've always wanted to grow my own cannabis plant. I don't drink alcohol or use tobacco, so this is the only thing I use," said Lavoie.

"[I'm challenging the government] really to grow at home and cut down on my personal consumption costs — and I want every Manitoban to have that right."

The case looks specifically at Section 101.15 of the Liquor, Gaming and Cannabis Control Act, amended in October 2018 to include cannabis, which states that a person must not cultivate the drug at their residence.

It also now states that a person cannot possess a total of 30 grams of weed in public, nor can a person possess cannabis that is not packaged, labelled and stamped in accordance with federal requirements, "unless permitted by regulation."

The penalty for breaking Section 101.15 of the legislation is a fine of $2,542.

The provincial legislation stands in contrast to Section 12 of the federal Cannabis Act, which states that up to four marijuana plants can be grown at a residence at one time.

"The pith and substance of the prohibition is to restrict access to cannabis in Manitoba and to establish an absolute criminal ban on residential cultivation of cannabis in Manitoba," the court document says.

"The purpose of the prohibition is to establish an absolute ban of a practice on the bases of moral values and social acceptability, and to replace, stiffen and strengthen the criminal law."

Because the ban is related to criminal law, the Manitoba government overstepped its authority because only the federal government has authority of criminal law, the court document says.

The section should also be stricken from the provincial legislation because it contradicts the federal rules, it adds.

There is precedent for the case. Quebec and Manitoba were the only two provinces to ban growing recreational cannabis at home until Sept. 3, 2019, when Quebec Superior Court Justice Manon Lavoie ruled that the ban was unconstitutional.

Homegrown cannabis makes cents
Lavoie consumes between one and two grams of marijuana per day, and the strain he likes costs $15 per gram at the recreational pot shop, he said.

But were he allowed to grow four marijuana plants at home, they could produce 400 grams every four months, assuming the plants were grown properly, Lavoie said.

"When you times 400 by the $15 per gram that I'm spending, that's impacting me financially massively," he said.

Cannabis can be stored from six to 12 months, so Lavoie could make the homegrown supply last most of the year, he said.

"That's affecting me. I'm sure it's affecting a lot of people financially, for those who want to try to grow. And in times of [COVID-19] when everyone's stuck at home and money is tight for a lot of people, it just makes sense," Lavoie said.

Despite marijuana being legal in Canada, the black market is still thriving, and many people are buying their pot online for four to five dollars per gram, said Lavoie, who has worked in the cannabis industry for three years.

"That's missed tax dollars in general for the government of Manitoba," he said. "But if they legalize growing at home, they can tax seeds, reoccurring. They can tax grow equipment, lights, dehumidifiers. People have more money to spend on cannabis accessories like vaporizers, water pipes.

"I don't see it as keeping the black market away. I see it as letting the legal market flourish in just another avenue."

Ultimately, Lavoie sees homegrown weed as a potential hobby for the public, similar to making beer or wine at home, he said.

Lavoie hired two lawyers from MLT Aikins, a Winnipeg firm, to take on the case. They will have to file an affidavit prior to a hearing scheduled on Sept. 28 in order to move the case forward.

Lavoie launched a GoFundMe campaign to help cover his legal fees. His goal is to reach $80,000 so he can afford to take the case to the Supreme Court, should the need arise.

Any unused funds will go directly to Winnipeg Harvest, Habitat for Humanity and the Manitoba Metis Heritage Fund.

Lavoie hopes the province will respond quickly to his case, so Manitobans won't lose more time on a potential harvesting.

To view Lavoie's Notice of Application please follow title link and scroll to the bottom of the article.


Vapor Accessory Addict
Staff member
Medical marijuana bust in NOTL

It’s one of the largest medical marijuana busts in the country. Niagara police raided a medical marijuana grow on Lakeshore in Niagara-on-the-lake and cut down and seized nearly 900 plants, worth $1.6 million dollars.

Outside and behind the greenhouse police found 843 large marijuana plants growing in the hoop houses and on the grounds. Growing marijuana outside is illegal. 11 people were arrested and the property was seized.

Hans Rannala lives next door and says this marijuana grow op has been here for a few years.

The government tried to shut these types of medical marijuana grows down, but they’ve challenged it in court.

“My hands were tied. Enforcement’s hands were tired. They couldn’t do anything until the grow op did something silly or stupid.”

The old rules wouldn’t allow town officials to check for bylaw infractions, but then they found out they were growing more than their licence allowed and that’s when police, fire officials and bylaw officers moved in.

Angus Footman is the head of Tweed marijuana. Tweed has a 350 000 square foot greenhouse in Niagara-on-the-lake which operates under the new tight regulations. The lakeshore greenhouse operates under the old rules.

“They operate under the old MMAR which has very little regulations, either for security or the way they produce medical cannabis.”

At Tweed every gram is monitored and recorded from seed to sale. Every movement on and around the property watched 24 hours a day.

Under the old medical marijuana rules a designated grower can produce pot for 2 people.

“And there’s no oversight by health Canada to verify the number of plants each grower has.”

The Lakeshore greenhouse had 4 separate legal grow licenses. Not one of the persons who had a licence was there at the time of the raid.

The fire department indicates that 11 people lived in the greenhouse and that has a number of fire code violations, propane and combustibles, with no smoke or CO alarm.


Vapor Accessory Addict
Staff member
Canada’s cannabis concentrate market slowly comes to life, revealing producers’ strategies

As cannabis concentrates become more widely available in Canada’s regulated adult-use marijuana market, new products illustrate the variety of roles such merchandise can fill for producers, including:

  • Premium concentrates aimed at cannabis users accustomed to black-market concentrates.
  • Simple concentrates created to entice consumers at relatively low price points.
  • A path to upgrade production byproducts into in-demand consumer goods such as hashish.
Early sales data from Canada’s concentrates market should be taken with a grain of salt.

Limited product availability in certain categories means concentrate shoppers have far fewer choices than they will when the market eventually matures, particularly versus other, more widely available refined cannabis products such as vape pens.

For example, Vivo Cannabis subsidiary ABcann Medicinals appears to be offering the only shatter currently available in Canada’s regulated market.

Still, Canada’s legal concentrate market is clearly growing, as is the market as a whole: Point-of-sales data from Seattle-based cannabis analytics firm Headset shows category sales in Ontario grew from roughly 43,000 Canadian dollars ($33,000) in February to nearly CA$359,000 in July, not including online sales from the government-operated online Ontario Cannabis Store.

Appealing to experienced consumers

Privately held British Columbia producer Good Buds sees top-notch concentrates as a path to enticing experienced cannabis consumers away from the illicit market.

Canada’s legal cannabis producers haven’t always offered those customers what they want, said Good Buds co-founder and Chief Strategy Officer Alex Rumi.

“I think it largely relates to a lot of the larger public companies having this really highly investor-focused mentality, especially leading into legalization in the early days,” he said.

“I think a lot of them are pivoting now, but it was a lot of focus on things that got investors excited, like vapes and edibles – there wasn’t really much of a focus on products like hash and rosin and even (butane hash oil) extractions, which are more legacy, black-market products that are very popular.”

Rumi said Good Buds’ goal is producing high-quality concentrates that appeal to heavy-using consumers who are accustomed to those illicit products.

To that end, Good Buds’ current concentrate portfolio includes a live hash extracted from fresh-frozen cannabis plants, a hash rosin pressed from that same live hash, and a flower rosin product pressed from hand-trimmed cannabis bud.

“Ours is definitely the connoisseur play,” Rumi said.

“(The target customer is) willing to spend a bit more on it, kind of like people that collect wine and things like that,” he continued.

Rumi believes there’s plenty of room for competition in Canada’s high-end concentrate market, particularly from other small producers.

“All these factors that drive our quality up are things that are hard to scale and hard to do at a really low cost,” he said.

Keeping concentrates simple

A number of Canadian producers have entered the concentrate space with solventless products, including kief and bubble hash.

In Alberta, “BC Kief” from Vivo Cannabis subsidiary Canna Farms has been the top-selling concentrate in terms of unit sales this year, according to market data from Headset.

Privately held B.C. producer Tantalus Labs has kicked off its concentrate portfolio with a dry sift hash, a powdery concentrate that hasn’t been pressed into a brick.

It’s made with dried, cured cannabis biomass, frozen solid and run through a tumbler to separate the trichome heads and capitate stalks.

CEO Dan Sutton described the concentrate as a simple product with high production efficiency.

“It’s easy for us to produce, we get to pass those savings on to the customer and at a price point that’s comparable to a lot of the other kief products in the market,” he said.

Sutton believes the younger generation of cannabis consumers gravitates toward concentrates such as shatter, diamonds and live resin, but he believes solventless products can offer those consumers a competitive value proposition.

“I think we’re converting users on the premise that this is a really low-cost product you can try, you don’t really have an excuse not to try it.”

Strong demand for hashish

Hashish has taken an early lead in the regulated concentrate markets in Ontario, B.C. and Alberta year-to-date, Headset point-of-sale data shows.

Hexo Corp.’s “Original Stash” hash product, sold in 2-gram packages, has become the best-selling concentrate product in all three provinces this year in dollar terms.

Hexo regulatory filings say the Original Stash hash is made using trim as the primary input, part of a “trim management initiative” meant to “systematically reduce this inventory on hand.”

Ontario producer 48North Cannabis launched a pressed-hashish product in B.C. in June and has since rolled it out to other provinces.

CEO Charles Vennat believes hash in its classic brick form benefits from an existing consumer base that has been waiting for it to arrive on the regulated market.

“I think a traditional pressed hash is a safe reintroduction back into cannabis for people who have maybe been sitting on the sidelines for a while and who maybe smoked it in high school and college,” he said.

Vennat believes a successful concentrates strategy can involve “cooking with what’s in the fridge.”

“In essence, what you’re doing is you’re taking what, in many ways, is considered a byproduct of your cultivation practice, and you’re turning it into a commercial consumer packaged good.”

Limited selection, high retail prices

Concentrate prices in the Canadian market remain relatively high: Headset point-of-sale data shows the average price for a gram of concentrate in July was CA$47.84 in Alberta, CA$39.23 in B.C., and CA$31.53 in Ontario, not including the government-operated Ontario Cannabis Store website.

Dan Sutton of Tantalus Labs attributes high prices in part to Canada’s federal excise tax structure for cannabis extracts, which taxes products such as edibles and concentrates based on their THC content.

“So essentially, the higher quality the hash, the more refined the hash … the higher your taxation level is going to be,” he said.

“It’s just one of those things – maybe it’ll change, maybe it won’t – but inevitably concentrates in general and solventless concentrates will have a higher cost profile than their illicit-market counterparts,” he said.

“And perhaps we combat that somehow with cost efficiency and moreover with product quality, over time.”

Vennat of 48North said he expects upcoming price compression in the concentrate market, but he believes that can be offset with new production innovations as demand for regulated concentrates increases and the market opportunity grows.

“The amount of engineering and capital (investment) that you can justify, then, into improving your process and improving your scalability of it, that’s what’s going to drive a lot of cost savings.”


Vapor Accessory Addict
Staff member
Petition Pushes for National Medical Cannabis Insurance For Canadians
Can Canadians soon have cannabis covered by insurance?

A new healthcare technology company, Cannalogue, is launching a petition in their native land of Canada to get the Ministries of Health on board with providing national healthcare coverage for medical cannabis.

The petition, entitled United for Access, was started because of the financial burden the COVID-19 pandemic has had on many Canadians, especially those who are already marginalized or disadvantaged, according to a press release the company sent out. Cannalogue believes Canadian citizens should have access to cannabis health care as well as general healthcare.

“More than 50 percent of Canadians are not able to afford treatment with medical cannabis including CBD for conditions such as chronic pain,” their website states. “Due to COVID-19, Cannalogue anticipates these figures will worsen given the economic challenges facing Canadians. The doctors at Cannalogue believe this will cause a spike in opioid prescriptions, resulting in more opioid related addictions and deaths. When safer medications like medical cannabis and CBD are available, all Canadians should have fair and equal access as part of universal healthcare. Sign the United Program for National Medical Cannabis Coverage petition today and join us as we fight to remove the barriers that prevent access to safer medicines for Canadians.”

Advocating For Cannabis Access
Cannalogue received attention in Canada recently for receiving the first direct-to-sales license for medical cannabis and introducing an online marketplace for cannabis shopping to help streamline cannabis consumption in the age of COVID and shopping from home. The company is physician-led, and they make it a point to advocate for cannabis access and make activism a part of their platform in addition to commerce and sales. They would like to see cannabis considered a viable alternative to opiate treatments in the years to come.

This is not the first time the company has advocated for cannabis access and patient access. The new petition, announced this week, was born from their Compassionate Care Program, a program that can be used to find discounts on medical cannabis products, especially for seniors, veterans, Indigenous people, disabled people, and those on some sort of federal assistance program.

“These are some of the most challenging times for Canadians—especially those who suffer from chronic conditions such as pain or anxiety,” says Dr. Mohan Cooray of Cannalogue. “Removing the barriers that prevent access to medical cannabis is the fundamental goal of Cannalogue and this petition will help us ensure that disadvantaged groups including those below the poverty line get the medications they need.”

“Cost continues to be one of the most substantial barriers facing patients using cannabis for medical purposes, and there is an unmet need for patients to receive expanded access to insurance coverage for their treatment,” says President and Board Chairperson Gerald Major of Medical Cannabis Canada, a cannabis patient advocacy group in Canada. “To address these issues, collaboration across industry, government and the non-profit sector is essential and we are excited to see this petition put pressure towards change.”

If this petition gains traction, Canada could make even more headlines with a comprehensive, cannabis healthcare program.


Vapor Accessory Addict
Staff member

Canadian student-athletes will no longer be tested for cannabis

The Canadian Centre for Ethics in Sport will stop screening student-athletes for cannabis in U Sports and the Canadian Collegiate Athletic Association, allowing athletes to test positive during in-competition months without penalty.

The summer's new policy change, however, does not extend to U Sports and CCAA student-athletes who also compete at the national level during their collegiate career. So student-athletes included in their sport’s National Athlete Pool, competing in a non-U Sports or non-CCAA event or attending an international event where the CCES does not have jurisdiction can still be screened for cannabis.

“The CCES has long advocated for cannabis not to be deemed a prohibited substance,” said Jeremy Luke, the senior director of sport integrity at the CCES. “We didn't see the performance enhancing benefit associated with [cannabis].”

With the legalization of marijuana in Canada two years ago, Luke said this was an opportune time to make the decision to stop screening for the drug.

The CCES has not received much feedback from the Canadian athletic community regarding the new policy change — however, Luke said the little response they have received has been positive.

The CCES says they'll continue to adapt to the changing sports landscape in Canada moving forward. The organization has informed member teams of U Sports and the CCAA about changes to its drug education courses and other resources the CCES offers for student-athletes.

“The mandatory learning program for student athletes has been revised to inform them of this change,” Luke explained, referring to the pre-season drug education course that student-athletes must complete before the start of the regular season each year. “We've issued advisory notes and some other resources as well so that people are well informed of the change.”

Luke said the CCES will continue to monitor Canadian collegiate sports to see if they will make any further changes.

At the moment, the CCES is not expecting to change the policy for U Sports and CCAA student-athletes who also compete at the national level, as they will continue to be screened for cannabis in-competition.

Sponsored by

PuffItUp Dynavap VGoodiez 420EDC